These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12678741)

  • 1. Recent progress in the development of anticancer agents.
    Eckhardt S
    Curr Med Chem Anticancer Agents; 2002 May; 2(3):419-39. PubMed ID: 12678741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
    Kerbel RS; Viloria-Petit A; Klement G; Rak J
    Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major contributions towards finding a cure for cancer through chemotherapy: a historical review.
    Masood I; Kiani MH; Ahmad M; Masood MI; Sadaquat H
    Tumori; 2016; 102(1):6-17. PubMed ID: 26350183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel targets for therapy in paediatric oncology.
    Estlin EJ
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Jul; 2(2):141-50. PubMed ID: 12476788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
    Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
    Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.
    Wahl O; Oswald M; Tretzel L; Herres E; Arend J; Efferth T
    Curr Med Chem; 2011; 18(21):3136-55. PubMed ID: 21671856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.
    Cepero V; Sierra JR; Giordano S
    Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel pharmacological agents in clinical development for solid tumours.
    Dy GK; Haluska P; Adjei AA
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2059-88. PubMed ID: 11772306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting human telomerase in cancer therapy.
    Huard S; Autexier C
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):577-87. PubMed ID: 12678725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic inhibitors: a new therapeutic strategy in oncology.
    Gasparini G; Longo R; Toi M; Ferrara N
    Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of drug resistance in cancer chemotherapy.
    Luqmani YA
    Med Princ Pract; 2005; 14 Suppl 1():35-48. PubMed ID: 16103712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
    Pourquier P; Pommier Y
    Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
    Wong MS; Sidik SM; Mahmud R; Stanslas J
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.